Researchers testing the experimental vaccine, GVAX, learned that it erases lung cancer in some patients and slows its spread in others, primarily in patients with non-small cell lung cancer that often is resistant to chemotherapy. The small study involved patients injected with GVAX, made by CellGenesis; the patients had no recurrence of their non-small cell lung cancer more than three years later, according to the report in Wednesday's Journal of the National Cancer Institute.

Related Summaries